Edgewise
Brief description of study
This is a 2-part, open-label study in approximately 9 adults with oHCM. Part A of the study consists of 3 cohorts of approximately 3 participants each administered a single dose of EDG-7500. Part B of the study is an optional multiple-dose treatment period in which approximately 9 participants will receive EDG-7500 once daily for up to 28 days (see Figure 1).
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Medical Research
-
Age: - 99 Years
-
Gender: All
TBD
Find a site
,
You have contacted , on
Your message has been sent to the study team at ,
What happens next?
- You can expect the study team to contact you via email or phone in the next few days.
- Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.
You are contacting
